All In Biotech

Drug Trial Radar · NCT07328919

Efficacy and Safety of TT-00420 (Tinengotinib) Tablets Versus Chemotherapy in Patients With Advanced Intrahepatic Cholangiocarcinoma Harboring FGFR2 Fusions/Rearrangements or Mutations

A Phase III, Randomized Controlled, Open-Label, Multicenter Clinical Study Evaluating the Efficacy and Safety of TT-00420 Tablets Versus Chemotherapy in Patients With Surgically Unresectable Advanced or Metastatic Intrahepatic Cholangiocarcinoma Harboring FGFR2 Fusions/Rearrangements or Mutations, Who Have Progressed or Relapsed After Prior First-Line Systemic Therapy

Last checked: Nov 19, 2026Latest source record: Jan 9, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Not yet recruitingPivotal-lookingPhase 3. Randomized with 138 participants. This is a heuristic, not a regulatory label.

Status

Not yet recruiting

Enrollment

138

Planned (sponsor's estimate)

Start

Jan 2026

Primary completion

Dec 31, 2029

Study completion Dec 31, 2030

Sponsor

Sponsor type
Industry
First posted
Jan 9, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is an open-label, randomized, controlled, multicenter, phase III clinical study designed to evaluate the efficacy and safety of TT-00420 tablets as monotherapy versus chemotherapy in subjects with unresectable advanced or metastatic intrahepatic cholangiocarcinoma harboring FGFR2 gene fusions/rearrangements or mutations, who have experienced recurrence or progression after prior first-line systemic chemotherapy.

Conditions

  • Intrahepatic Cholangiocarcinoma (Icc)
  • Advanced Cholangiocarcinoma

Interventions

  • TT-00420 (tinengotinib)Drug

    Subject will receive TT-00420 (tinengotinib) once daily in 28-day cycles with initial dosage of 10 mg QD per protocol defined schedule.

  • Oxaliplatin, fluorouracil, calcium folinate, irinotecan, capecitabineDrug

    Subjects will receive chemotherapy (mFOLFOX regimen, XELIRI regimen, or irinotecan monotherapy). The dosing schedule involves intravenous administration or oral intake every two weeks (except for capecitabine). Treatment continues until the occurrence of confirmed disease progression, intolerable toxicities, withdrawal of informed consent, death, or other reasons specified in the protocol (whichever occurs first). Among these, subjects receiving the mFOLFOX regimen are limited to a maximum of 6 treatment cycles (approximately 12 administrations).

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. PFS by BICRTime frame: From first study drug administration until the date of first documented progression assessed by BICR or date of death from any cause, whichever came first, assessed up to 24 months.

Locations

20 sites in 1 country. Site status is shown where the registry gives one.

  • Beijing Cancer Hospital

    Beijing, China

  • Beijing Tsinghua Changgung Hospital

    Beijing, China

  • Cancer Hospital, Chinese Academy of Medical Sciences

    Beijing, China

  • Peking Union Medical College Hospital

    Beijing, China

  • Eastern Hepatobiliary Surgery Hospital

    Shanghai, China

  • Fudan University Shanghai Cancer Hospital

    Shanghai, China

  • Zhongshan Hospital, Fudan University

    Shanghai, China

  • Anhui Provincial Hospital

    Hefei, Anhui, China

  • Fujian Cancer Hospital

    Fuzhou, Fujian, China

  • Zhujiang Hospital of Southern Medical University

    Guangzhou, Guangdong, China

  • The First Affiliated Hospital of Zhengzhou University

    Zhengzhou, Henan, China

  • Zhongnan hospital of Wuhan University

    Wuhan, Hubei, China

  • Hunan Cancer Hospital

    Changsha, Hunan, China

  • Nanjing Drum Tower Hospital

    Nanjing, Jiangsu, China

  • The First Affiliated Hospital of Nanchang University

    Nanchang, Jiangxi, China

  • Jinan Central Hospital

    Jinan, Shandong, China

  • Shandong Cancer Hospital

    Jinan, Shandong, China

  • Sichuan Cancer Hospital

    Chengdu, Sichuan, China

  • West China Hospital of Sichuan University

    Chengdu, Sichuan, China

  • Zhejiang Cancer Hospital

    Hangzhou, Zhejiang, China

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.